Citigroup’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Citigroup’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.39M	Sell	50,000 -190,000	-79%	-$23.7M	﹤0.01%	1776
2025 Q4	$29.3M	Sell	240,000 -10,600	-4%	-$1.22M	0.01%	891
2025 Q3	$25.1M	Buy	250,600 +80,600	+47%	+$7.26M	0.01%	941
2025 Q2	$14.1M	Buy	170,000 +70,000	+70%	+$5.58M	0.01%	1168
2025 Q1	$8.11M	Buy	+100,000	New	+$8.94M	﹤0.01%	1514
2024 Q4	–	Sell	-20,000	Closed	-$1.98M	–	5979
2024 Q3	$1.98M	Sell	20,000 -30,000	-60%	-$2.95M	﹤0.01%	2677
2024 Q2	$4.64M	Hold	50,000	–	–	﹤0.01%	1684
2024 Q1	$4.74M	Sell	50,000 -35,900	-42%	-$3.33M	﹤0.01%	1748
2023 Q4	$7.67M	Sell	85,900 -59,100	-41%	-$4.39M	0.01%	1343
2023 Q3	$10.6M	Sell	145,000 -5,000	-3%	-$399K	0.01%	1077
2023 Q2	$12.5M	Sell	150,000 -5,000	-3%	-$418K	0.01%	1038
2023 Q1	$11.8M	Buy	155,000 +106,700	+221%	+$8.85M	0.01%	1082
2022 Q4	$4.01M	Sell	48,300 -40,000	-45%	-$3.24M	﹤0.01%	1579
2022 Q3	$7M	Sell	88,300 -390,000	-82%	-$32.9M	0.01%	1350
2022 Q2	$35.5M	Buy	478,300 +330,000	+223%	+$24.8M	0.03%	521
2022 Q1	$13.3M	Sell	148,300 -726,700	-83%	-$67.1M	0.01%	1147
2021 Q4	$98M	Buy	+875,000	New	+$106M	0.05%	331
2021 Q3	–	Sell	-10,000	Closed	-$1.35M	–	6352
2021 Q2	$1.35M	Buy	+10,000	New	+$1.31M	﹤0.01%	2986
2021 Q1	–	Sell	-96,200	Closed	-$13.5M	–	7521
2020 Q4	$13.5M	Sell	96,200 -52,200	-35%	-$6.69M	0.01%	1320
2020 Q3	$16.5M	Sell	148,400 -70,500	-32%	-$7.9M	0.01%	1012
2020 Q2	$24.5M	Buy	218,900 +35,400	+19%	+$3.49M	0.02%	716
2020 Q1	$14.2M	Sell	183,500 -48,400	-21%	-$4.29M	0.01%	934
2019 Q4	$22.1M	Sell	231,900 -77,500	-25%	-$6.7M	0.02%	908
2019 Q3	$23.6M	Buy	309,400 +86,700	+39%	+$7.21M	0.02%	824
2019 Q2	$19.5M	Sell	222,700 -16,500	-7%	-$1.41M	0.02%	944
2019 Q1	$21.7M	Sell	239,200 -90,100	-27%	-$7.66M	0.02%	787
2018 Q4	$23.6M	Buy	329,300 +77,600	+31%	+$6.25M	0.02%	727
2018 Q3	$24.1M	Sell	251,700 -15,100	-6%	-$1.46M	0.02%	729
2018 Q2	$25.4M	Sell	266,800 -143,900	-35%	-$13.2M	0.02%	660
2018 Q1	$36M	Sell	410,700 -9,500	-2%	-$867K	0.03%	511
2017 Q4	$35.7M	Buy	420,200 +200,100	+91%	+$16.8M	0.03%	557
2017 Q3	$19.1M	Buy	220,100 +60,200	+38%	+$4.83M	0.02%	823
2017 Q2	$12.3M	Sell	159,900 -199,900	-56%	-$14.2M	0.01%	1012
2017 Q1	$24.9M	Buy	359,800 +215,000	+148%	+$14.4M	0.02%	661
2016 Q4	$8.57M	Buy	144,800 +10,400	+8%	+$642K	0.01%	1319
2016 Q3	$8.91M	Sell	134,400 -526,700	-80%	-$32.6M	0.01%	1170
2016 Q2	$35.8M	Buy	661,100 +582,800	+744%	+$31.9M	0.04%	418
2016 Q1	$4.04M	Buy	78,300 +10,500	+15%	+$545K	﹤0.01%	1747
2015 Q4	$4.75M	Hold	67,800	–	–	﹤0.01%	1745
2015 Q3	$4.22M	Buy	67,800 +44,100	+186%	+$3.48M	﹤0.01%	1807
2015 Q2	$1.99M	Sell	23,700 -9,300	-28%	-$723K	﹤0.01%	2515
2015 Q1	$2.48M	Buy	+33,000	New	+$2.31M	﹤0.01%	2297

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Citigroup's XBI Position: Q1 2026 in Review

Citigroup reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, selling an estimated $233M and leaving 10,663,404 shares worth $1.36B. The position accounts for 0.58% of the portfolio, ranked #27.

Citigroup first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.53B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Citigroup held 10,663,404 shares of State Street SPDR S&P Biotech ETF worth $1.36B as of Q1 2026.
Citigroup sold 1,863,806 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $233M.
State Street SPDR S&P Biotech ETF made up 0.58% of Citigroup's portfolio in Q1 2026, its #27 holding.
Citigroup first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
Citigroup's State Street SPDR S&P Biotech ETF position peaked at $1.53B in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.